Allogene Therapeutics, Inc.

ALLO· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$1.08-8.05%

2026-11-02

Financials

Valuation Metrics

Allogene Therapeutics, Inc.'s Market Cap is $374M. At end of 2025 it was $302M. Ranked #2811 of 3,118 in US market (top 90%), #1240 of 1,474 on NASDAQ (top 84%), #223 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 84%) by Market Cap.

Investment Metrics(as of 2026-11-02)

Metric	Value	Rank
Size
Market Cap	$374M	US#2,811/3,118 Sec#223/265
Revenue	$5M	US#2,822/3,118 Sec#178/265
Net Income	$-165M	US—/3,118 Sec—/265
Total Assets	$550M	US#2,723/3,118 Sec#152/265
Net Assets	$436M	US#2,306/3,118 Sec#122/265
Value
P/B	0.86x	US#351/3,118 Sec#21/265
P/S	80.71x	US#2,937/3,118 Sec#176/265
FCF Yield	-27.40%	US—/3,118 Sec—/265
Profitability
ROE	-37.94%	US#2,607/3,118 Sec#130/265
ROA	-30.08%	US#2,876/3,118 Sec#156/265
Op. Margin	-3886.14%	US#2,824/3,118 Sec#174/265
Financial Health
Debt Ratio	26.12%	US#291/3,118 Sec#95/265
Total Debt	$70M	US#2,522/3,118 Sec#139/265
FCF	$-103M	US#2,634/3,118 Sec#147/265
Cash	$39M	US#2,677/3,118 Sec#237/265
Current Ratio	10.72x	US#223/3,118 Sec#70/265
Performance
1Y Return	-12.50%	US#1,911/3,118 Sec#153/265
1M Return	-27.67%	US#2,935/3,118 Sec#242/265
From 52W High	-75.67%	US#3,004/3,118 Sec#243/265
1Y MDD	-64.54%	US#2,762/3,118 Sec#210/265
Trading
Volume	8,083,936 shares	US#206/3,118 Sec#10/265
Trading Value	$9M	US#2,236/3,118 Sec#173/265
Per Share
EPS	$-0.48	US—/3,118 Sec—/265
BPS	$1.26	US#2,653/3,118 Sec#193/265